Volver al artículo.

Referencias para el artículo

1. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164–7.
2. Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev 1990;11:386–98.
3. Lee JR. Osteoporosis reversal: the role of progesterone. Int Clin Nutr Rev 1990;10:384–91.
4. Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61–5.
5. Leonetti HB, Longo S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225–8.
6. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. Comp Ther 1998;24:336–9.
7. Freeman E, Rickels K, Sondheimer SJ, et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA. 1990;264:349–53.
8. Leonetti HB, Long S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obtstet Gynecol 1999;94:225–8.
9. Lobo RA, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1–5
10. Skegg DCG, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer; a pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995;273:799–804.
11. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9.
12. Chang KJ, Fournier S, Lee TTY, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91.
13. Söderqvist G, Isaksson E, von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Obstet Gynecol 1997;176:123–8.
14. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981;114:209–17.
15. Mohr PE, Wang DY, Gregory WM, et al. Serum progesterone and prognosis in operable breast cancer. Br J Cancer 1996;73:1552–5.
16. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981;114:209–17.
17. Plu-Bureau G, Lê MG, Thalabard MC, et al. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Detect Prev 1999;23:290–6.
18. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217–21.
19. Rosano GMC. Presentation to the American Heart Association’s Scientific Sessions. New Orleans, Louisiana, 1996.
20. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. Comp Ther 1998;24:336–9 [review].
21. Araghiniknam M, Chung S, Nelson-White T, et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sci 1996;11:147–57.
22. Dollbaum CM. Lab analyses of salivary DHEA and progesterone following ingestion of yam-containing products. Townsend Letter for Doctors and Patients: Oct 1995, 104.
23. Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989;73:606–12.
24. Hargrove JT, Osteen KG. An alternative method of hormone replacement therapy using the natural sex steroids. Infert Repro Med Clin N Am 1995;6:653–74.
25. Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet 1998;351:1255–56 [letter] and Lancet 1998;352:905–6 [comments].
26. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol. 1985;151:746–50.
27. Hargrove JT, Osteen KG. An alternative method of hormone replacement therapy using the natural sex steroids. Infert Repro Med Clin N Am 1995;6:653–74.